Caribou Biosciences, Inc. Estimated Litigation Liability
Caribou Biosciences, Inc. (CRBU) had Estimated Litigation Liability of $3.90 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LitigationReserve · last filed 2024-11-06
- 2024-09-30: Estimated Litigation Liability $3.90M.
- 2024-06-30: Estimated Litigation Liability $3.90M.
- 2024-03-31: Estimated Litigation Liability $3.90M.
- 2023-12-31: Estimated Litigation Liability $0.00.
| Period end | Estimated Litigation Liability |
|---|---|
| 2024-09-30 | $3.90M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $3.90M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.90M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |